Hypothesis\nNAD+ decline does not merely reflect damage; it actively amplifies the senescence‑associated secretory phenotype (SASP) by suppressing SIRT1 deacetylase activity, thereby unleashing NF‑κB‑driven transcription of pro‑inflammatory cytokines and CD38. This creates a feed‑forward loop where rising CD38 consumes more NAD+, further inhibiting SIRT1 and sustaining SASP.\n\n## Mechanistic Rationale\nSIRT1 requires NAD+ to deacetylate p65 NF‑κB, keeping it transcriptionally quiet. When NAD+ falls, p65 remains acetylated, NF‑κB translocates to the nucleus, and drives expression of IL‑6, IL‑8, and CD38 itself [1][2]. Senescent cells already secrete SASP factors that induce CD38 [2]; low NAD+ deepens this signal by removing SIRT1’s brake. Concurrently, PARP1 hyperactivation—triggered by accumulating DNA damage—competes for the dwindling NAD+ pool, lowering SIRT1 activity even further [3]. The net effect is a metabolic‑inflammatory circuit that converts NAD+ loss from a passive biomarker into an active driver of chronic inflammation.\n\n## Testable Predictions\n1. Pharmacological elevation of NAD+ (e.g., NMN) in old mice will reduce SASP factor secretion and lower CD38 expression in tissues, independent of senescent‑cell clearance.\n2. SIRT1 overexpression in senescent cells will blunt NF‑κB activation and decrease CD38 transcription even when NAD+ is low.\n3. Simultaneous inhibition of CD38 and activation of SIRT1 will synergistically lower circulating IL‑6 and improve metabolic readouts more than either intervention alone.\n\n## Experimental Design\n- Animal cohorts: 24‑month‑old C57BL/6 mice split into four groups (vehicle, NMN, SIRT1‑overexpressing AAV, NMN + SIRT1‑OE).\n- Readouts: Tissue NAD+ levels (mass spectrometry), SIRT1 activity (deacetylase assay), nuclear p65 acetylation (Western blot), CD38 mRNA/qPCR, SASP cytokines (ELISA), and senescent‑cell burden (p16^INK4a immunohistochemistry).\n- Intervention duration: 8 weeks.\n- Statistical analysis: ANOVA with post‑hoc Tukey; significance set at p < 0.05.\n\nIf NAD+ restoration lowers SASP and CD38 without reducing senescent‑cell numbers, the hypothesis gains support. Conversely, if NAD+ boost fails to attenuate SASP despite raising NAD+, the feed‑forward model would be refuted, pointing to alternative drivers of inflammation.\n\n[1] https://doi.org/10.1016/j.cmet.2018.03.016\n[2] https://doi.org/10.1016/j.bbrc.2019.03.199\n[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC4911708/